MTMichael T. Truver

Michael T. Truver

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael T. Truver has a total of 108 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intoxications and fatalities associated with the ingestion of the novel synthetic cathinone, N -isopropyl butylone

    by Munchelou M Gomonit, Sara E Walton, Michael T Truver, Chris W Chronister, Donna M Papsun, Alex J Krotulski, Bruce A Goldberger, Barry K Logan

    Synthetic cathinones represent an expanding class of novel psychoactive substances (NPS), with their proliferation largely driven by international drug control measures and the rapid cycling of structural analogues designed to circumvent legislative scheduling. Following the international control of N, N-dimethylpentylone (DMP) in 2024, N-isopropyl butylone (NiPB) was increasingly detected in forensic toxicological casework as the prevalence of DMP declined. However, limited data currently exist regarding NiPB’s concentration ranges in forensic investigations. This report describes a validated liquid chromatography-tandem quadrupole mass spectrometry (LC-QQQ-MS) method for the quantitation of NiPB in biological specimens, which was applied to the analysis of drugged driving (n = 1) and postmortem (n = 15) cases. The driving under the influence of drugs case yielded a NiPB blood concentration of 16 ng/mL, whereas the remaining 15 cases demonstrated blood concentrations ranging from <1 to 1400 ng/mL. For one case, NiPB was quantitated in blood, vitreous fluid, and urine, with concentrations of 18, 17, and 2200 ng/mL, respectively. Polydrug use was observed for all cases and frequently involved fentanyl (75%), cocaine and/or methamphetamine (69%), other synthetic cathinones (25%), ethanol (31%), and additional NPS such as bromazolam (19%) and MDMB-4en-PINACA (13%). Concentrations overlapped between antemortem and postmortem cases and were comparable to those reported for structurally related beta-keto methylenedioxyamphetamines, suggesting that members of this analogue class may share similar patterns of use and toxicological profiles. Although NiPB was identified as a contributing factor in several fatalities, the lack of pharmacological and toxicological data limits further interpretation of measured concentrations and the extent of its contribution to these fatal outcomes. Additional studies incorporating paired central and peripheral blood specimens are warranted to better characterize potential postmortem redistribution and its impact on NiPB blood concentration interpretation. Overall, this case series addresses a critical literature gap on NiPB by providing analytical and interpretive data to support forensic laboratories as NiPB identifications increase within the evolving NPS stimulant market.

  • Postmortem case series of Δ8- and Δ9-tetrahydrocannabinol in blood and urine

    by Munchelou M. Gomonit, Marco Ballotari, Michael T. Truver, Sara C. Brogan, Jennifer L. Hoyer, Bruce A. Goldberger, Chris W. Chronister

    The growing popularity of delta-8-tetrahydrocannabinol (Δ8-THC) products has introduced new analytical and interpretive challenges for forensic toxicology laboratories. While delta-9-tetrahydrocannabinol (Δ9-THC) and its metabolites have been extensively characterized in postmortem casework, comparable data for Δ8-THC remain scarce. This study presents a validated LC-MS/MS method for the quantitation of Δ8-THC, Δ9-THC, and their primary metabolites in postmortem blood. Sample preparation employed liquid-liquid extraction using water acidified with 10% acetic acid, followed by extraction with hexane: ethyl acetate (90:10, v/v). The validated method was subsequently applied to a selected subset of authentic postmortem blood samples (n = 107) previously identified to contain Δ8- and/or Δ9-THC-COOH by GC-MS urine testing. Among these cannabinoid-positive urine cases, 39.3% were positive in blood for both Δ8- and Δ9-THC and their metabolites, whereas 25.2% and 14.0% were positive for only Δ8-THC and Δ9-THC-related analytes, respectively. Δ8-THC blood concentrations ranged from 1.0 to 90.4 ng/mL, and Δ8-THC-COOH concentrations ranged from 5.1 to 1484 ng/mL. Additionally, 11-OH-Δ8-THC was measured in 11.2% of cases and consistently co-occurred with Δ8-THC and Δ8-THC-COOH. These findings provide descriptive postmortem concentration data for Δ8-THC and highlight the importance of adequate chromatographic resolution of THC isomers. Importantly, we also underscore the interpretive challenges of polycannabinoid findings in postmortem casework, where detection of Δ8-THC, Δ9-THC, and/or their metabolites should be interpreted as evidence of cannabinoid exposure, and not as definitive evidence of impairment, intoxication, or contribution to death without additional case context.

  • Prevalence of p -fluorofentanyl and xylazine in postmortem fentanyl casework

    by Marco Ballotari, Michael T Truver, Jennifer L Hoyer, Bruce A Goldberger, Chris W Chronister

    In the United States (U.S.), fentanyl remains the leading drug associated with opioid-related deaths. Many analogs of fentanyl have been identified and linked to the opioid overdose epidemic. After core-structure scheduling of illicitly manufactured fentanyl (IMF) and related products, para-fluorofentanyl (p-FF) reemerged with varied prevalence in the U.S. Xylazine also emerged as a cutting agent in IMF. The aim of this study was to describe the prevalence and trend use patterns of fentanyl, p-FF, and xylazine in a case series from 2021 to 2023 in the state of Florida. A three-year retrospective analysis of data was conducted. A total of 8121 cases were submitted for analysis over the period of study. Among them, 1530 cases (18.8%) tested positive for fentanyl in one or more of the specimens submitted for these cases. The age of the decedents ranged 16–85 years, with the majority being White males. The concentration range of fentanyl in the blood specimens (n = 1358) analyzed was 2.5–579 ng/mL. p-FF was detected with fentanyl in 164 postmortem blood specimens with a concentration range of 2.5–65 ng/mL. Xylazine was identified in the urine of 391 decedents. The combination of fentanyl, p-FF, and xylazine was detected in 70 cases. When fentanyl co-occurred with both xylazine and p-FF, it was primarily observed with benzodiazepines, cocaine, methamphetamine, and other opioids. This study aimed to provide a better understanding of the fentanyl analog and adulterant prevalence in Florida.

  • Blood pharmacokinetics and use of metabolite-to-parent ratios to predict time of last zopiclone intake

    by Munchelou M Gomonit, Gunnel H Nilsson, Ingrid Nyström, Liselotte Berglund, Fredrik C Kugelberg, Maria D Chermá, Johan Ahlner, Michael T Truver, Robert Kronstrand

    Zopiclone (ZOP) is a sedative-hypnotic drug that is featured commonly in impaired driving, drug-facilitated crimes, accidental overdose, or suicidal intoxications. Further understanding of its blood pharmacokinetics would support its interpretation in forensic toxicology casework. This study characterizes the concentration-time pharmacokinetic profiles of ZOP and its metabolite N-desmethylzopiclone (N-DMZOP) in blood following controlled administration and evaluates the use of metabolite-to-parent ratios in estimating time of last ZOP intake. Sixteen subjects received a single oral dose of either 5 mg or 10 mg Imovane®, and blood samples were collected pre-dosing, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 24, and 48 hours post-dose. A paired plasma sample was also provided at the 2-hour time point. A previously validated LC–MS/MS method was used to quantify ZOP, N-DMZOP, and the degradation product 2-amino-5-chloropyridine (ACP). The aggregate regression model developed from this younger subject population was applied to independently dosed subjects and a separate group of elderly patients to determine the validity of this model in an older cohort of differing pharmacokinetic characteristics. Comparison between the 5 mg and 10 mg dosing groups supported a linear dose-concentration relationship. While the ratio of N-DMZOP/ZOP can be a predictive indicator for time of ZOP intake, inter-individual differences in ZOP disposition may influence such predictions. Furthermore, age-related pharmacokinetic changes may contribute to a general underestimation of predicted time with the current model, but a larger sample size of a broader demographic spectrum and dosing regimen would help improve the general applicability of this ratio-based modeling. Finally, we show that the mean blood-to-plasma ratio for ZOP and N-DMZOP were 0.79 and 0.92, respectively, suggesting a preferential partitioning of ZOP into the plasma fraction, which would be a useful reference when interpreting plasma concentrations from clinical studies against the more routinely sampled whole blood concentrations found in forensic toxicological casework.

  • Fatal intoxications with nitazenes: postmortem findings, toxicology, and in vitro characterization at the μ-opioid receptor of six nitazene analogues

    by Michael T. Truver, Markus Roman, Munchelou M. Gomonit, Henrik Gréen, Robert Kronstrand, Mattias Persson

    Nitazenes constitute a structurally diverse class of non-fentanyl synthetic opioids that have rapidly emerged in the European illicit drug market since 2019. Bridging analytical, seized drug epidemiology, and interpretative gaps would support meaningful interpretation of nitazene-related deaths. This study presents a fit-for-purpose LC–MS/MS method for the quantitation of six nitazenes, etazene, isotonitazene, N-pyrrolidino isotonitazene, metonitazene, N-pyrrolidino metonitazene, and protonitazene in postmortem blood. The method was applied to analyze 57 nitazene-positive autopsy cases received between December 2020 and December 2024 by the Swedish National Board of Forensic Medicine. During this period, metonitazene (n = 38) and protonitazene (n = 10) were the most encountered nitazenes, with femoral blood concentrations in mono-intoxicated cases ranging from 0.3 to 34 ng/g and 1.7 to 4.9 ng/g respectively. Complementary in vitro MOR activation studies using AequoScreen® assays demonstrated that these nitazenes possess potencies (0.17–6.0 nM) and efficacies comparable to, or exceeding, those of fentanyl. The predominance of metonitazene prompted further investigation into its metabolism and stability profile, where analysis of authentic postmortem cases indicated the presence of three possible metabolites (N-desethyl, acetamido, 5-amino metonitazene) alongside other amino-containing degradation products. Further studies elucidating true metabolites from postmortem or storage-related breakdown products would support interpretation of nitazene exposure in casework. These findings provide an overview of nitazenes in Swedish forensic casework and address a critical gap in region-specific data, underscoring the need for sustained analytical vigilance and proactive toxicovigilance strategies to ensure timely detection and accurate interpretation of nitazene-related mortalities in an evolving drug landscape.


  • An enduring threat: NPS benzodiazepines in forensic and clinical toxicology from 2021 to 2025

    by Kayla N Ellefsen, Erin L Karschner, Sandrine A M Mérette, Amy L Patton, Elisa N Shoff, Christina R Smith, Michael T Truver, Dani C Mata, Donna M Papsun

    The proliferation and sustained detection of novel psychoactive benzodiazepines in forensic and clinical toxicology, combined with their potential for adverse events, poses an enduring threat to public health and safety with complex characteristics and challenges unique from other subclasses of novel psychoactive substances (NPS). This study aimed to systematically review the published effects, observations, and toxicological data from postmortem and human performance studies [including clinical, driving under the influence of drugs (DUID), and drug-facilitated crimes (DFC)] involving NPS benzodiazepines from 2021 to 2025. The challenges this class of compounds presents to clinicians, toxicologists, and medical professionals were also addressed, including both analytical and interpretative challenges. Literature reviews were performed in PubMed, Google Scholar, Google Search, toxicology journals, and conference abstract proceedings using search terms such as “NPS benzodiazepines,” “designer benzodiazepines,” and compound specific searches; authoritative websites such as NPS Discovery, National Forensic Laboratory Information System, and the European Union Drug Agency were also consulted. A total of 259 NPS benzodiazepine-related studies were identified including 29 postmortem, 15 DUID, 27 clinical, and 5 DFC studies detailed in this review. NPS benzodiazepines were widely pervasive in both postmortem and human performance cases with overlapping toxic and recreational concentrations; often involving polysubstance use with other central nervous system depressants and stimulants. Unique clinical presentations, observed effects, and autopsy findings were also reported for NPS benzodiazepines. This review provides an updated, consolidated resource to support toxicologists and clinicians in interpretation, emerging risk assessment, and evolving challenges associated with NPS benzodiazepines across postmortem and human performance settings.


  • Δ 8 ‐tetrahydrocannabinol, Δ 9 ‐tetrahydrocannabinol, and cannabidiol carboxylic acid metabolites in authentic meconium samples

    by Marco Ballotari, Michael T. Truver, Chris W. Chronister, Jennifer L. Hoyer, Kay Roussos‐Ross, Amie J. Goodin, Sarah H. Bartock, Tiara Evans, Wen Dui, Bruce A. Goldberger

    The consumption of cannabis‐related products during pregnancy is increasing. Marijuana (cannabis) use during pregnancy, whether for nonmedical or medical purposes to relieve of pregnancy‐related symptoms and discomfort, can lead to potential adverse clinical and neurodevelopmental outcomes for the developing fetus. Testing conventional matrices, such as blood and urine, provides information regarding the recent intake of drugs, whereas analysis of alternative specimens, such as meconium, provides information regarding maternal use and potential in utero exposure during the third trimester of pregnancy. In this study, meconium samples ( n = 19) were obtained from neonates at birth delivered at the University of Florida (UF). All the mothers participating in the study completed a questionnaire regarding cannabis and cannabidiol (CBD) use during pregnancy. Maternal urine samples were also collected during each trimester of pregnancy and at delivery. 11‐nor‐Δ 9 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 9 ‐THC‐COOH), 11‐nor‐Δ 8 ‐tetrahydrocannabinol‐9‐carboxylic acid (Δ 8 ‐THC‐COOH) and 7‐carboxy cannabidiol (7‐COOH‐CBD) were quantitated in the meconium samples utilizing liquid chromatography‐tandem mass spectrometry (LC–MS/MS). The most frequently identified analyte was Δ 9 ‐THC‐COOH (median concentration: 113 ng/g) which was quantitated in the meconium samples ( n = 12) of neonates born to mothers who self‐reported cannabis use during the third trimester. Δ 8 ‐THC‐COOH was observed in five of the Δ 9 ‐THC‐COOH positive samples (median concentration: 15.7 ng/g). Meconium of neonates born to mothers who did not self‐report a history of cannabis use (control subjects) was negative for Δ 8 ‐THC‐COOH and Δ 9 ‐THC‐COOH. These data support further study of drug use patterns during pregnancy to focus on the clinical consequences of use during the perinatal period.

  • Prevalence of N,N-Dimethylpentylone in forensic toxicology casework: A retrospective study and trends in the state of Florida

    by Marco Ballotari, Michael T. Truver, Elisa N. Shoff, Nicholas B. Tiscione, Kristin W. Kahl, Diane M. Moore, Lisa J. Reidy, Bruce A. Goldberger, Chris W. Chronister


  • Case series involving the synthetic cathinones alpha-PHP, alpha-PiHP, MDPHP, and MDPiHP in forensic investigations

    by Munchelou M. Gomonit, Sara E. Walton, Donna M. Papsun, Michael E. Lamb, Chris W. Chronister, Alex J. Krotulski, Simon Elliott, Kerry Taylor, Michael T. Truver, Bruce A. Goldberger, et al.


  • Metabolite ratios and detection times in urine following a single dose of zopiclone

    by Munchelou M. Gomonit, Gunnel H. Nilsson, Ingrid Nyström, Liselotte Berglund, Fredrik C. Kugelberg, Johan Ahlner, Michael T. Truver, Robert Kronstrand